Profile: Adamas Pharmaceuticals Inc (ADMS.OQ)
24 May 2019
Adamas Pharmaceuticals, Inc., incorporated on November 15, 2000, is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. The Company offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. The Company has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. The Company's first product candidate is ADS-5102, which is a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). The Company has completed Phase II proof-of-concept study of ADS-5102 in these patients.
The Company's Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. The Company's second product candidate is ADS-4101, which is an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures). ADS-4101 is in Pre-Investigational New Drug (IND) stage. The Company is also conducting trial for EASE LID 2, an open-label safety study. The Company owns commercialization rights of two drugs commercially available in the United States, including NAMENDA XR (memantine hydrochloride) extended-release capsules and NAMZARIC (memantine hydrochloride extended-release and donepezil hydrochloride) capsules.
Adamas Pharmaceuticals Inc
1900 Powell St Ste 1000
EMERYVILLE CA 94608-1839